BIIB peers and competitors
Biogen Inc. · end-of-day data as of Oct 16, 2026
Biogen Inc.
$232.65+15.1%
Buy · 37 analystsPT $238.98 +2.7%
BIIB’s peers by industry and size include Eli Lilly (LLY), Johnson & Johnson (JNJ) and AbbVie (ABBV). Among these 12 companies BIIB ranks 9th by market cap ($34.37B); its P/E of 41.2 compares with a median of 38.7 for its peers.
Peers by industry and size
| 20D | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1 |  | $1,257.03 | +0.4% | -1.8% | +4.5% | 42.2 | $1.18T | |
| 2 |  | $255.56 | +0.9% | -8.2% | +8.8% | 38.7 | $616B | |
| 3 |  | $285.42 | +0.7% | 0.0% | -1.4% | 80.4 | $504B | |
| 4 |  | $145.95 | +0.5% | -6.2% | +7.7% | 116.8 | $360B | |
| 5 |  | $432.49 | -0.4% | -2.6% | -7.5% | 26.9 | $234B | |
| 6 |  | $156.19 | -0.7% | -0.7% | +1.9% | — | $194B | |
| 7 |  | $29.58 | +0.5% | 0.0% | -7.1% | 39.1 | $169B | |
| 8 |  | $59.75 | -1.4% | -11.3% | +9.4% | 13.2 | $122B | |
| 9 | | $232.65 | -1.1% | -1.1% | +2.7% | 41.2 | $34.37B | |
| 10 |  | $69.16 | -1.9% | -1.9% | -0.5% | — | $34.16B | |
| 11 |  | $238.97 | -1.3% | -12.7% | +3.7% | 23.0 | $33.61B | |
| 12 |  | $79.38 | +1.2% | -45.2% | +24.2% | 13.1 | $32.78B |
Data as of Oct 16, 2026 close.